tradingkey.logo


Medpace Holdings Inc

MEDP

437.780USD

-10.140-2.26%
āļ›āļīāļ” 07/30, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
12.27BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
29.46P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Medpace Holdings Inc āļšāļĢāļīāļĐāļąāļ—
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™MEDP
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Medpace Holdings Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļAug 11, 2016
āļāđˆāļ­āļ•āļąāđ‰āļ‡āđ€āļĄāļ·āđˆāļ­2014
āļ‹āļĩāļ­āļĩāđ‚āļ­Dr. August J. Troendle, M.D.
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™5900
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Aug 11
āļ—āļĩāđˆāļ­āļĒāļđāđˆ5375 Medpace Way
āđ€āļĄāļ·āļ­āļ‡CINCINNATI
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ Global Select Consolidated
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ45227-1543
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ15135799911
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://investor.medpace.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™MEDP
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļAug 11, 2016
āļāđˆāļ­āļ•āļąāđ‰āļ‡āđ€āļĄāļ·āđˆāļ­2014
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
962.62K
-4.80%
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
36.50K
--
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
26.22K
+0.24%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
10.34K
-22.48%
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
833.00
+7.35%
Dr. Dani S. Zander
Dr. Dani S. Zander
Independent Director
Independent Director
--
--
Mr. Cornelius P. Mccarthy, III
Mr. Cornelius P. Mccarthy, III
Independent Director
Independent Director
--
--
Mr. Kevin M. Brady
Mr. Kevin M. Brady
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Fred B. Davenport, Jr.
Mr. Fred B. Davenport, Jr.
Lead Independent Director
Lead Independent Director
--
--
Ms. Susan E. Burwig
Ms. Susan E. Burwig
Executive Vice President - Operations
Executive Vice President - Operations
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
962.62K
-4.80%
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
36.50K
--
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
26.22K
+0.24%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
10.34K
-22.48%
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
833.00
+7.35%
Dr. Dani S. Zander
Dr. Dani S. Zander
Independent Director
Independent Director
--
--
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 14 āļž.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 14 āļž.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Medpace Investors, L.L.C.
16.85%
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.60%
Troendle (August J)
3.43%
Wasatch Global Investors Inc
2.95%
Other
59.18%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Medpace Investors, L.L.C.
16.85%
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.60%
Troendle (August J)
3.43%
Wasatch Global Investors Inc
2.95%
Other
59.18%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
51.46%
Investment Advisor/Hedge Fund
27.05%
Corporation
16.85%
Hedge Fund
5.94%
Individual Investor
4.19%
Pension Fund
2.66%
Family Office
2.20%
Research Firm
2.14%
Family Office
1.65%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
1164
31.76M
110.49%
-2.18M
2025Q1
1189
32.19M
111.84%
-1.65M
2024Q4
1154
31.87M
104.30%
-1.77M
2024Q3
1089
31.75M
102.26%
-1.23M
2024Q2
1042
31.55M
102.01%
-1.83M
2024Q1
995
31.67M
102.27%
-1.17M
2023Q4
938
31.80M
103.67%
-407.87K
2023Q3
885
31.39M
102.53%
-1.87M
2023Q2
840
32.05M
105.05%
-2.06M
2023Q1
794
33.14M
108.15%
-529.32K
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Medpace Investors, L.L.C.
4.73M
16.47%
--
--
Mar 20, 2025
The Vanguard Group, Inc.
2.53M
8.79%
-37.16K
-1.45%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.41M
8.4%
-38.83K
-1.58%
Mar 31, 2025
Troendle (August J)
1.01M
3.52%
+356.45K
+54.45%
Mar 20, 2025
Wasatch Global Investors Inc
829.46K
2.89%
-107.38K
-11.46%
Mar 31, 2025
State Street Global Advisors (US)
782.99K
2.72%
+3.17K
+0.41%
Mar 31, 2025
Mawer Investment Management Ltd.
696.22K
2.42%
+309.23K
+79.91%
Mar 31, 2025
Geode Capital Management, L.L.C.
668.20K
2.32%
+12.07K
+1.84%
Mar 31, 2025
Bessemer Trust Company, N.A. (US)
582.27K
2.03%
+6.22K
+1.08%
Mar 31, 2025
Renaissance Technologies LLC
577.69K
2.01%
+24.10K
+4.35%
Mar 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Franklin Genomic Advancements ETF
3.73%
Argent Mid Cap ETF
2.79%
Congress SMid Growth ETF
2.18%
Capital Group US Small and Mid Cap ETF
2.16%
ERShares Entrepreneurs ETF
1.99%
First Trust NASDAQ Pharmaceuticals ETF
1.81%
Aztlan Global Stock Selection DM SMID ETF
1.79%
Invesco S&P MidCap 400 GARP ETF
1.75%
Invesco S&P MidCap Quality ETF
1.56%
ROBO Global Healthcare Technology & Innovation ETF
1.51%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Franklin Genomic Advancements ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.73%
Argent Mid Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.79%
Congress SMid Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.18%
Capital Group US Small and Mid Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.16%
ERShares Entrepreneurs ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.99%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.81%
Aztlan Global Stock Selection DM SMID ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.79%
Invesco S&P MidCap 400 GARP ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.75%
Invesco S&P MidCap Quality ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.56%
ROBO Global Healthcare Technology & Innovation ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.51%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™